Recombinant lipid-tagged antibody fragments as functional cell-surface receptors

Nature Medicine

Volumn 6, Issue 2, 2000, Pages 223-227

  De Kruif, John ^a,b   Tijmensen, Marella ^b   Goldsein, Joel ^c   Logtenberg, Ton ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Utrecht Biotechnology Systems   (Netherlands)

^c MEDAREX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; PEPTIDE FRAGMENT; RECOMBINANT ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DNA TRANSFER; GENE THERAPY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY;

AMINO ACID SEQUENCE; ANTIGENS, CD; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIPID METABOLISM; MOLECULAR SEQUENCE DATA; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; VACCINES;

EID: 0033961486     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/72339     Document Type: Article

References (27)

1. Laukkanen, M.L., Teeri, T.T. & Keinanen, K. Lipid-tagged antibodies Bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein. Protein Eng. 6, 449-454 (1993).
2. Laukkanen, M.L., Alfthan, K. & Keinanen, K. Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody Biochemistry 33, 11664-11670 (1994).
3. de Kruif, J., Storm, G. van Bloois, L. & Logtenberg, T. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett. 399, 232-236 (1996).
4. de Kruif, J., Boel, E. & Logtenberg, T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248, 97-105 (1995).
5. de Kruif, J., Terstappen, L., Boel, E. & Loglenberg, T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sci. USA 92, 3938-3942 (1995).
6. Graziano, R.F. et al. Construction and characterization of a humanized anti-gamma-lg receptor type I (FcyRI) monoclonal antibody. J. Immunol. 155, 4996-5002 (1995).
7. Pack, P. et al. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coll. Bio/technology 11, 1271-1277 (1993).
8. Grayeb, J. & Inouye, M. Nine amino acid residues at the NH2-terminal of lipoprotein are sufficient for its modification, processing and localization in the outer membrane of Escherichia coli. J. Biol. Chem, 259, 463-467 (1984).
9. Grouard, G., de Boutteiller, O., Banchereau, J. & Liu, Y. -J. Human follicular dendritic cells enhance cytokine-dependent growth and differentiation of CD40-activated B-cells. J. Immunol. 155, 3345-3352 (1995).
10. Smiths, G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317 (1985).
11. Francisco, J.A., Earhart, C.F. & Georgiou, G. Transport and anchoring of beta-lactamase to the external surface of Escherichia coli. Proc. Natl. Acad. Sci. USA 89, 2713-2717 (1992).
12. Boder, E.T. & Wittrup, K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nature Biotechnol. 15, 553-557 (1997).
13. Eshhar, Z. Tumor-specific T-bodies: Towards clinical application. Cancer Immunol. Immunother. 45, 131-136 (1997).
14. Kwiatkowska, K. & Sobota, A. Signaling pathways in phagocytosis. BioEssays 21, 422-431 (1999).
15. Devitt, A. et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392, 505-509 (1998).
16. Sallusto, F & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109-1114 (1994).
17. Gosselin, E.J. et al. Enhanced antigen presentation using human Fcyreceptor (monocyte/macrophage)-specific immunogens. J. Immunol. 149, 3477-3481 (1992).
18. Liu, C. et al. FcyRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and agonist T-cell epitopes. J. Clin. Invest. 98, 2001-2007 (1999).
19. + T-helper and a T-killer cell. Nature 393, 474-478 (1998).
20. Bennett, S.R.M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
21. Schoenberger, S.P., Toes, R.E.M., van der Voort, E.I.H., Offringa, R. & Melief, C.J.M. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
22. Nawrocki, S. & Mackiewicz, A. Genetically modified tumour vaccines - where we are today. Cancer Treat. Rev 25, 29-46 (1999).
23. Schirrmacher, V. et al. Human tumor cell modification by virus infection. Gene Ther. 6, 63-73 (1999).
24. Haas, C., Herold-Mende, C., Gerhards, R. & Schirrmacher, V. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules. Cancer Gene Ther. 6, 254-262 (1999).
25. Berd, D et al. Autologous, hapten-modified vaccine as a treatment for human cancers Semin. Oncol. 25, 646-653 (1998).
26. Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. 3, 558-561 (1997).
27. Vermerken, J.B. et al. Active specific immunotherapy for stage II and stage III human colon cancer: A randomized trial. Lancet 353, 345-350 (1999).